Jazz’s development pipeline includes the clinical development of new therapies to treat unmet medical needs, line extensions for existing products, and the generation of additional clinical data for existing products.
1 NDA submissions assume positive study outcomes.
2 Evaluation of deuterated oxybate continues as part of the once-nightly development process; JZP-386 formulation work ongoing.
3 Evaluating early stage product candidates, including recombinant pegaspargase.
AML = Acute Myeloid Leukemia, NDA = New Drug Application, MAA = Marketing Authorization Application, ES = Excessive Sleepiness, OSA = Obstructive Sleep Apnea, EDS = Excessive Daytime Sleepiness, sNDA = Supplemental New Drug Application, VOD = Hepatic Veno-occlusive Disease, FPI = First Patient In, GvHD = Graft versus Host Disease, ALL = Acute Lymphoblastic Leukemia